SCHEMBL23067180

SCHEMBL23067180

Cc1c(CC(NC(=O)O)C(=O)NN)ccc(O)c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 5/20 0.39
▸ FNTB P49356 5/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.35
▸ ESR2 Q92731 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ ADORA3 P0DMS8 2/20 0.35
▸ PTGS2 P35354 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ ESR1 P03372 1/20 0.35
▸ NPY1R P25929 1/20 0.35
▸ OPRD1 P41143 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ HK2 P52789 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ THPO P40225 1/20 0.35
▸ POLB P06746 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29687718 0.84 CTSS (0.44) MAPT
SCHEMBL5384282 0.81 FNTA (0.39) FNTAFNTBKMT2AKDM4EESR2
SCHEMBL28731419 0.76 KDM4E (0.33) KMT2AKDM4EESR2ALDH1A1ADORA3
SCHEMBL3467175 0.73 SLC7A5 (0.54) KMT2AKDM4EALDH1A1ADORA3PTGS2
SCHEMBL3467173 0.73 SLC7A5 (0.54) KMT2AKDM4EALDH1A1ADORA3PTGS2
SCHEMBL23067398 0.71 AOC2 (0.41) KMT2AKDM4EESR2ALDH1A1ADORA3
SCHEMBL18262789 0.71 KMT2A (0.51) KMT2AALDH1A1POLBNPSR1GNPAT
SCHEMBL18262792 0.71 KMT2A (0.51) KMT2AALDH1A1POLBNPSR1GNPAT
SCHEMBL3782261 0.69 KMT2A (0.66) KMT2AKDM4EMEN1LMNAMAPT
SCHEMBL23067414 0.69 GAA (0.46) KDM4EALDH1A1CYP3A4CYP2C9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4028404-A2 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS Tennor Therapeutics Limited (CN) 2022-07-20 — — EP disclosed
US-11040987-B2 Penam derivatives for treating bacterial infections TENNOR THERAPEUTICS LIMITED (CN) 2021-06-22 — — US disclosed
WO-2021048613-A2 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS TENNOR THERAPEUTICS LIMITED (CN) 2021-03-18 — — WO disclosed
US-20210070774-A1 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS TENNOR THERAPEUTICS LIMITED (CN) 2021-03-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070774-A1 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS BPGM, BLVRB, PREP FNTA 381/4885FNTB 138/4885KMT2A 1018/4885
US-11040987-B2 Penam derivatives for treating bacterial infections BPGM, BLVRB, PREP FNTA 381/4885FNTB 138/4885KMT2A 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback